0000000000223461

AUTHOR

A. M. Offidani

showing 4 related works from this author

HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa

2019

Background: Hidradenitis suppurativa (HS) is a chronic, relapsing, inflammatory skin disease characterized by painful inflamed nodules, recurrent abscesses and fistulas located in apocrine gland–bearing body sites. The negative impact of HS on patient's quality of life (QoL) has been reported to be greater than other dermatologic conditions as psoriasis and atopic eczema, and its improvement is an important goal in disease management. Nowadays, there are no specific validated QoL instruments available for HS and generic dermatologic questionnaires are used. Objective: The objective of this study was to demonstrate the validity, reliability and responsiveness of HIDRAdisk, a new innovative t…

MalePsychometricsVisual Analog ScaleIntraclass correlationAcne ‐ RosaceaHIDRAdiskLongitudinal StudieSeverity of Illness Index030207 dermatology & venereal diseases0302 clinical medicineQuality of lifeSurveys and QuestionnairesHidradenitis suppurativa030212 general & internal medicineLongitudinal StudiesIMPACT IMPAIRMENT VALIDITY DISEASE.HIDRAdisk Hidradenitis Suppurativa Quality of Life Validation study Visual toolValidation studyDermatology Life Quality IndexMiddle AgedhumanitiesInfectious DiseasesHIDRAdisk; Hidradenitis Suppurativa; Quality of Life; Validation study; Visual toolItalyhidradenitis suppurativa; visual analog scale; quality of LifeFemaleOriginal ArticleSettore MED/35 - MALATTIE CUTANEE E VENEREEVisual toolPsychometricHumanAdultmedicine.medical_specialtyPsychometricsVisual analogue scaleReproducibility of ResultDermatology03 medical and health sciencesYoung AdultCronbach's alphaInternal medicineSeverity of illnessmedicineHumansbusiness.industryhidradenitis suppurativaReproducibility of Resultsmedicine.diseaseQuality of Lifebusiness
researchProduct

Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study

2021

BACKGROUND The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far. OBJECTIVES To identify clinical parameters predicting response to adalimumab and confirm its efficacy/safety. METHODS The data of 389 patients with HS treated with adalimumab in 21 Italian centres were reviewed. Sex, age at onset/diagnosis/baseline, body mass index, smoking, phenotype, previous treatments, concomitant antibiotics and 'therapeutic delay', defined as the time from HS onset to adalimumab initiation, were assessed. Response to adalimumab and its impact on quality of life (QoL) wer…

medicine.medical_specialtyVisual analogue scaleAnti-Inflammatory AgentsDermatologySeverity of Illness Index030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineSettore MED/35Quality of lifeInternal medicineSeverity of illnessmedicineAdalimumabHumansHidradenitis suppurativahidrosadenitis suppurativaRetrospective Studiesbusiness.industryAdalimumabRetrospective cohort studyOdds ratioDermatology Life Quality Indexmedicine.diseasehumanitiesHidradenitis SuppurativaTreatment OutcomeQuality of LifeAdalimumab Hidradenitis Suppurativa quality of lifeSettore MED/35 - MALATTIE CUTANEE E VENEREEbusinessmedicine.drug
researchProduct

Reciprocal altered expression of E-cadherin and P-cadherin in mucous membrane pemphigoid.

2011

E- and P- cadherins are involved in the selective adhesion of epidermal cells. To gain insight into the role of cadherins on the acantholysis of keratinocytes and further investigate the pathogenesis of Mucous Membrane Pemphigoid, we examined the expression of P-cadherin and E-cadherin, in normal human oral mucosa, lesional and peri-lesional mucosa in MMP. Twenty-nine samples from paraffin-embedded specimens of MMP were used for the study. Five specimens of healthy oral mucosa were evaluated as control group. To evaluate the E- and P-Cadherin expression, a mean percentage of positive cells was determined from the percentage of positive cells derived from the analysis of 100 cells in ten ra…

AdultMalePathologymedicine.medical_specialtyPemphigoidmucous pemphigoidBlistering disease; E-cadherin; Mucous Membrane Pemphigoid; P-cadherin;Blistering diseaseImmunologySettore MED/50 - Scienze Tecniche Mediche ApplicatePemphigoid Benign Mucous MembraneMucous Membrane PemphigoidHuman skinBiologyP-cadherinPathogenesisDownregulation and upregulationSettore MED/28 - Malattie OdontostomatologichemedicineImmunology and AllergyHumansOral mucosaAgedPharmacologyAged 80 and overCadherinAcantholysismucous pemphigoid; cadherinMouth MucosaE-cadherinMiddle Agedmedicine.diseaseCadherinsEpitheliummedicine.anatomical_structurecadherinCase-Control StudiesFemaleInternational journal of immunopathology and pharmacology
researchProduct

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

2020

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is creating an unprecedented global public health emergency with the continuous growth of infected individuals worldwide. Italy was one of the first European country to face the first wave of infection outside mainland China. The first case of COVID-19 was confirmed in Lombardy on February 20th , 2020, and subsequently, a rapid increase in the number of detected cases was observed, spreading through Italy and the rest of Europe.3 As of April 22nd , confirmed COVID-19 cases in Italy were 183,957.

medicine.medical_specialtyTildrakizumabBiolgical therapy; COVID-19; PsoriasisSettore MED/35PsoriasisChronic Disease; Emergencies; Humans; Italy; Psoriasis; Biological Therapy; COVID-19UstekinumabmedicineAdalimumabHumansPsoriasisbiologicsIntensive care medicineLetter to the Editorpsoriasipsoriasis; biologics; covid-19; pandemicEmergenciePsoriasiRisankizumabbusiness.industrySARS-CoV-2pandemicBiolgical therapyCOVID-19medicine.diseasedermatologyBiological TherapyIxekizumabGuselkumabInfectious Diseasescovid-19ItalyChronic DiseaseSecukinumabEmergenciesbusinessSettore MED/35 - MALATTIE CUTANEE E VENEREEbiologicCOVID-19 psoriasis biological therapiesmedicine.drugHuman
researchProduct